Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Gutman, Julie ^a   Kachur, S ^a   Slutsker, Laurence ^b   Nzila, Alexis ^c   Mutabingwa, Theonest ^d  

^a Malaria Branch   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

^d HUBERT KAIRUKI MEMORIAL UNIVERSITY   (Tanzania)

Author keywords

Malaria; Pregnancy; Probenecid; Sulphadoxine pyrimethamine

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CHLORCYCLOGUANIL; CHLOROTHIAZIDE; DAPSONE; FOLINIC ACID; GANCICLOVIR; INDOMETACIN; KETOPROFEN; KETOROLAC; LORAZEPAM; METHOTREXATE; MIDAZOLAM; NAPROXEN; NITRAZEPAM; OSELTAMIVIR; PARACETAMOL; PENICILLIN DERIVATIVE; PROBENECID; PYRIMETHAMINE; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFADIAZINE; SULFADOXINE; TAZOBACTAM; UNINDEXED DRUG; VALGANCICLOVIR; ZALCITABINE; ZIDOVUDINE; ZOMEPIRAC; ANTIMALARIAL AGENT; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

AGRANULOCYTOSIS; ALLERGIC PNEUMONITIS; ANAPHYLAXIS; ANEMIA; APLASTIC ANEMIA; BLOOD; CHOLESTATIC HEPATITIS; CONGENITAL TOXOPLASMOSIS; DIARRHEA; DRUG COST; DRUG HALF LIFE; DRUG WITHDRAWAL; ECLAMPSIA; EOSINOPHILIA; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; GONORRHEA; GOUT; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPERURICEMIA; HYPOTENSION; IMMUNOPATHOLOGY; LEUKOPENIA; LIVER NECROSIS; LIVER TOXICITY; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; MEDICAL RESEARCH; MEGALOBLASTIC ANEMIA; NAUSEA; NEPHROTIC SYNDROME; NEUTROPENIA; NONHUMAN; PLASMODIUM FALCIPARUM; PREECLAMPSIA; PREGNANCY; PRURITUS; RASH; REVIEW; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING; VULVOVAGINITIS; CHEMOPROPHYLAXIS; DRUG COMBINATION; FEMALE; METHODOLOGY; PREGNANCY COMPLICATION;

ANTIMALARIALS; CHEMOPREVENTION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROBENECID; PYRIMETHAMINE; SULFADOXINE; TREATMENT OUTCOME;

EID: 84856771745     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-39     Document Type: Review

References (98)

1. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. ter Kuile FO, van Eijk AM, Filler SJ, JAMA 2007 297 2603 2616 10.1001/jama.297.23.2603 17579229 (Pubitemid 46961032)
2. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, et al. Lancet 2009 374 1533 1542 10.1016/S0140-6736(09)61258-7 19765816
3. Impact of intermittent preventive treatment with sulphadoxine- pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. Dicko A, Sagara I, Sissoko M, Guindo O, Diallo A, Kone M, Toure O, Sacko M, Doumbo O, Malar J 2008 7 123 10.1186/1475-2875-7-123 18611271
4. Protective efficacy of malaria case management and intermittent preventive treatment for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. Thwing J, Eisele TP, Steketee RW, BMC Publ Health 2011 11 Suppl 3 14 10.1186/1471-2458-11-S3-S14
5. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). Wilson A, IPTc Taskforce, PLoS One 2011 6 16976 10.1371/journal.pone.0016976 21340029
6. Review: Intermittent preventive treatment - a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Greenwood B, Trop Med Int Health 2006 11 983 91 10.1111/j.1365-3156.2006.01657.x 16827699 (Pubitemid 44015237)
7. Intermittent preventive treatment of malaria in infants: how does it work and where will it work? Gosling RD, Carneiro I, Chandramohan D, Trop Med Int Health 2009 14 1003 1010 10.1111/j.1365-3156.2009.02303.x 19558374
8. Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in Mali: a randomized controlled trial. Maiga OM, Kayentao K, Traoré BT, Djimde A, Traoré B, Diallo M, Ongoiba A, Doumtabé D, Doumbo S, Traoré MS, Dara A, Guindo O, Karim DM, Coulibaly S, Bougoudogo F, Ter Kuile FO, Danis M, Doumbo OK, Clin Infect Dis 2011 53 215 223 10.1093/cid/cir374 21765069
9. Susceptibility of Plasmodium falciparum to antimalarial drugs: Report on global monitoring: 1996-2004. World Health Organization, Technical document WHO/HTM/MAL/20051103 Geneva: World Health Organization 2005
10. High resistance of Plasmodium falciparu to sulphadoxine/pyrimethamine in Northern Tanzania and the emergence of dhps resistance mutation at codon 581. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D, PLoS One 2009 4 4569 10.1371/journal.pone.0004569 19238219
11. World Health Organization, Guidelines for the treatment of malaria Geneva: WHO 2 2010
12. Competitive facilitation of drug-resistant Plasmodium falciparu malaria parasites in pregnant women who receive preventive treatment. Harrington WE, Mutabingwa TK, Muehlenbachs A, Sorensen B, Bolla MC, Fried M, Duffy PE, Proc Natl Acad Sci USA 2009 106 9027 9032 10.1073/pnas.0901415106 19451638
13. Intermittent Treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE, Clin Infect Dis 2011 53 224 230 10.1093/cid/cir376 21765070
14. Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. Feng G, Simpson JA, Chaluluka E, Molyneux ME, Rogerson SJ, PLoS One 2010 5 12012 10.1371/journal.pone.0012012 20700457
15. Intermittent preventive treatment against malaria: an update. Gosling RD, Cairns ME, Chico RM, Chandramohan D, Expert Rev Anti Infect Ther 2010 8 589 606 10.1586/eri.10.36 20455687
16. Therapeutic potential of folate uptake inhibition in Plasmodium falciparu. Nzila AM, Kokwaro G, Winstanley PA, Marsh K, Ward SA, Trends Parasitol 2004 20 109 112 10.1016/j.pt.2003.12.005 16676416 (Pubitemid 38264440)
17. Chemosensitization of Plasmodium falciparu by Probenecid In Vitro. Nzila A, Mberu E, Bray P, Kokwaro G, Winstanley P, Marsh K, Ward S, Antimicrob Agents Chemother 2003 47 2108 2112 10.1128/AAC.47.7.2108-2112.2003 12821454 (Pubitemid 36753558)
18. Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparu gametocytes in children with acute, uncomplicated malaria. Sowunmi A, Adedeji AA, Fateye BA, Fehintola FA, Ann Trop Med Parasitol 2004 98 873 878 10.1179/000349804X3243 15667719 (Pubitemid 40013193)
19. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Falade CO, Tambo E, Fateye BA, Happi TC, Oduola AMJ, Trop Med Int Health 2004 9 606 614 10.1111/j.1365-3156.2004.01233.x 15117306 (Pubitemid 38657287)
20. Spread and evolution of Plasmodium falciparu drug resistance. Mita T, Tanabe K, Kita K, Parasitol Int 2009 58 201 209 10.1016/j.parint.2009.04.004 19393762
21. Intermittent Presumptive Treatment for Malaria. White NJ, PLoS Med 2005 2 3 10.1371/journal.pmed.0020003 15696210 (Pubitemid 40412728)
22. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparu malaria. Kublin J, Dzinjalamala F, Kamwendo D, Malkin E, Cortese J, Martino L, Mukadam R, Rogerson S, Lescano A, Molyneux M, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, J Infect Dis 2002 185 380 388 10.1086/338566 11807721 (Pubitemid 34107252)
23. Mechanisms of resistance of malaria parasites to antifolates. Gregson A, Plowe CV, Pharmacol Rev 2005 57 117 145 10.1124/pr.57.1.4 15734729 (Pubitemid 40283971)
24. The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Watkins WM, Mberu EK, Winstanley PA, Plowe CV, Parasitol Today 1997 13 459 464 10.1016/S0169-4758(97)01124-1 15275132 (Pubitemid 127752379)
25. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Nyunt MM, Adam I, Kayentao K, van Dijk J, Thuma P, Mauff K, Little F, Cassam Y, Guirou E, Traore B, Doumbo O, Sullivan D, Smith P, Barnes KI, Clin Pharmacol Ther 2009 87 226 234 19776738
26. PROBENECID (BENEMID) Its Uses and Side-Effects in 2,502 Patients. Boger WP, Strickland SC, AMA Arch Intern Med 1955 95 83 92 10.1001/archinte.1955. 00250070099012 13217507
27. Clinical pharmacokinetics of probenecid. Cunningham R, Israili ZH, Dayton PG, Clin Pharmacokinet 1981 6 135 151 10.2165/00003088-198106020-00004 7011657 (Pubitemid 12164164)
28. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW, Cunningham F, Lin ET, Olivo N, et al. Antimicrob Agents Chemother 2008 52 3013 3021 10.1128/AAC.00047-08 18559644
29. Population pharmacokinetics of oseltamivir when coadministered with probenecid. Rayner CR, Chanu P, Gieschke R, Boak LM, Jonsson EN, J Clin Pharmacol 2008 48 935 947 10.1177/0091270008320317 18524996 (Pubitemid 352009487)
30. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. Wolf DL, Rodriguez CA, Mucci M, Ingrosso A, Duncan BA, Nickens DJ, J Clin Pharmacol 2003 43 43 51 10.1177/0091270002239705 12520627 (Pubitemid 36015442)
31. Probenecid Oral. http://www.medscape.com/druginfo/dosage?drugid= 8697&drugname=probenecid+Oral&monotype=default Accessed March 9, 2011
32. Renal transport of organic anions. Roch-Ramel F, Curr Opin Nephrol Hypertens 1998 7 517 524 10.1097/00041552-199809000-00006 9818198 (Pubitemid 28475290)
33. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H, J Biol Chem 1999 274 13675 13680 10.1074/jbc.274.19.13675 10224140 (Pubitemid 29220510)
34. Expression cloning and characterization of a novel multispecific organic anion transporter. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H, J Biol Chem 1997 272 18526 18529 10.1074/jbc.272.30.18526 9228014 (Pubitemid 27318187)
35. Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. Uwai Y, Okuda M, Takami K, Hashimoto Y, Inui K, FEBS Lett 1998 438 321 324 10.1016/S0014-5793(98)01328-3 9827570 (Pubitemid 28529298)
36. Co-administration of Probenecid, an inhibitor of a cMOAT/MRP- like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo. Sirotnak FM, Wendel HG, Bornmann WGB, Tong WP, Miller VA, Scher HI, Kris MG, Clin Cancer Res 2000 6 3705 3712 10999764
37. Resistance mechanisms to methotrexate in tumors. Bertino JR, Goker E, Gorlick R, Li WW, Banerjee D, Oncologist 1996 1 223 226 10387992 (Pubitemid 126669381)
38. Antagonism of sulfadoxine and pyrimethamine antimalarial activity in vitro by p-aminobenzoic acid, p-aminobenzoylglutamic acid and folic acid. Watkins WM, Sixsmith DG, Chulay JD, Spencer HC, Mol Biochem Parasitol 1985 14 55 61 10.1016/0166-6851(85)90105-7 3885030 (Pubitemid 15171429)
39. A modified in vitro sulfadoxine susceptibility assay for Plasmodium falciparu suitable for investigating Fansidar resistance. Wang P, Sims PF, Hyde JE, Parasitology 1997 115 Pt 3 223 230 9300459 (Pubitemid 27394548)
40. The antimalarial triazine WR99210 and the prodrug PS-15: folate reversal of in vitr activity against Plasmodium falciparu and a non- antifolate mode of action of the prodrug. Kinyanjui SM, Mberu EK, Winstanley PA, Jacobus DP, Watkins WM, AmJTrop Med Hyg 1999 60 943 947 (Pubitemid 29296219)
41. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria. van Hensbroek MB, Morris-Jones S, Meisner S, Jaffar S, Bayo L, Dackour R, Phillips C, Greenwood BM, Trans R Soc Trop Med Hyg 1995 89 672 676 10.1016/0035-9203(95)90438-7 8594693 (Pubitemid 26016360)
42. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of Plasmodium falciparum isolates from Kenyan coast: Emergence of parasites with Ile-164-Leu mutation. Kiara SM, Okombo J, Masseno V, Mwai L, Ochola I, Borrmann S, Nzila A, Antimicrob Agents Chemother 2009 53 3793 3798 10.1128/AAC.00308-09 19528269
43. Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. Sowunmi A, Adedeji AA, Fateye BA, Babalola CP, Parasite 2004 11 317 323 15490757 (Pubitemid 40022644)
44. Transfer of probenecid and cephalexin into breast milk. Ilett KF, Hackett LP, Ingle B, Bretz PJ, Ann Pharmacother 2006 40 986 989 10.1345/aph.1G580 16551765 (Pubitemid 43765021)
45. Anderson R, Gambertoglio JG, Schrier RW, Clinical use of drugs in renal failure Springfield, Il: Charles C Thomas 1976
46. Probenecid pharmacokinetics in cystic fibrosis. Weber A, de Groot R, Ramsey B, Williams-Warren J, Smith A, Dev Pharmacol Ther 1991 16 7 12 1879255
47. Pharmacokinetics of probenecid following oral doses to human volunteers. Selen A, Amidon GL, Welling PG, J Pharm Sci 1982 71 1238 1242 10.1002/jps.2600711114 7175716 (Pubitemid 13230064)
48. Product Information: Benemid(R), probenecid tablets: Merck & Company. West Point, PA 1998
49. Bennett W, Aronoff GR, Golper TA, Morrison G, Singer I, Brater DC, Drug prescribing in renal failure Philadelphia: American College of Physicians 1987
50. Fansidar. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id= 522&CFID=67813412&CFTOKEN=75538191fb984739-503250B9-9088-62D0- 8FF3FAD9D8ECF54A&jsessionid=ca303b8ac4d678123f51 Accessed March 9, 2011
51. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Peters PJ, Thigpen MC, Parise ME, Newman RD, Drug Saf 2007 30 481 501 10.2165/00002018-200730060-00003 17536875 (Pubitemid 46873074)
52. Monograph-Pyrimethamine, Sulfadoxine and Pyrimethamine. http://www.medscape.com/druginfo/monograph?cid=med&drugid=5911&drugname= pyrimethamine+Oral&monotype=monograph&secid=10 Accessed March 9, 2011
53. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. Green MD, van Eijk AM, van ter Kuile FO, Ayisi JG, Parise ME, Kager PA, Nahlen BL, Steketee R, Nettey H, J Inf Dis 2007 196 1403 1408 10.1086/522632 (Pubitemid 351412014)
54. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Karunajeewa HA, Salman S, Mueller I, Baiwog F, Gomorrai S, Law I, Page-Sharp M, Rogerson S, Siba P, Ilett KF, Davis TM, Antimicrob Agents Chemother 2009 53 4368 4376 10.1128/AAC.00335-09 19620325
55. Treatment of gonorrhea in pregnancy. Goodrich JT, Sex Transm Dis 1979 6 2 168 173 10.1097/00007435-197904000-00023 158835
56. Swanson M, Cook R, Drugs, chemicals and blood dyscrasias Hamilton, Il: Drug Intell Publications 1977
57. Drug induced hemolytic anemias associated with glucose-6-phosphate dehydrogenase deficiency: a genetically heterogenous trait. Marks PA, Banks J, Ann N Y Acad Sci 1965 123 198 206 14329202
58. Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. Chan T, Todd D, Tso SC, BMJ 1976 2 1227 1229 10.1136/bmj.2.6046.1227 990860
59. The hemolytic effect of certain drugs in Bantu subjects with a deficiency of glucose 6 phosphate dehydrogenase. Zail S, Charlton RW, Bothwell TH, S Afr Med J 1972 27 95 99
60. Glucose-6-phosphate dehydrogenase deficiency. Cappellini MD, Fiorelli G, Lancet 2008 371 64 74 10.1016/S0140-6736(08)60073-2 18177777
61. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M, Drug Saf 2010 33 713 726 10.2165/11536520-000000000-00000 20701405
62. Immune hemolytic anemia associated with probenecid. Sosler S, Behzad O, Garratty G, Lee CL, Postoway N, Khomo O, Am J Clin Pathol 1985 84 391 394 4036870 (Pubitemid 15235220)
63. Probenecid induced immune hemolytic anemia. Kickler T, Buck S, Ness P, Shirey RS, Sholar PW, J Rheumatol 1986 13 208 209 3701734 (Pubitemid 16118753)
64. Nephrotic syndrome caused by probenecid. Ferris TF, Morgan WS, Levitin H, NEJM 1961 265 381 383 10.1056/NEJM196108242650807 13699173
65. Probenecid-induced nephritic syndrome. Hertz P, Yager H, Richardson JA, Arch Pathol 1972 94 241 243 5051645
66. Probenecid-induced membranous nephropathy. Izzedine H, Brocheriou I, Becart J, Deray G, Nephrol Dial Transplant 2007 22 2405 2406 17510101
67. Probenecid, nephrotic syndrome, and renal failure. Scott J, O'Brien PK, Ann Rheum Dis 1968 27 249 252 10.1136/ard.27.3.249 5655316
68. Nephrotic syndrome caused by probenecid. Sokol A, Bashner MH, Okun R, JAMA 1967 199 43 44 10.1001/jama.1967.03120010087026 6071127
69. Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. Reynolds ES, Schlant RC, Gonick HC, Dammin GJ, NEJM 1957 256 592 596 10.1056/NEJM195703282561304 13451901
70. Probenecid Hypersensitivity in AIDS: a Case Report. Myers K, Katial RK, Engler RJ, Ann Allergy Asthma Immunol 1998 80 416 418 10.1016/S1081-1206(10) 62994-8 9609613 (Pubitemid 28246774)
71. (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine (Cidofovir): results of a phase i/ii study of a novel antiviral nucleotide analogue. Lalezari JP, Drew WL, Glutzer E, James C, Miner D, Flaherty J, Fisher PE, Cundy K, Hannigan J, Martin JC, Jaffe HS, J Inf Dis 1995 171 788 796 10.1093/infdis/171. 4.788
72. Zidovudine with probenecid: a warning. Petty B, Kornhauser D, Lietman P, Lancet 1990 335 1044 1045 1970102 (Pubitemid 20148641)
73. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Polis MA, Spooner KM, Baird BF, Manischewitz JF, Jaffe HS, Fisher PE, Falloon J, Davey RT Jr, Kovacs JA, Walker RE, Antimicrob Agents Chemother 1995 39 882 886 7785989
74. Acute anaphylactoid reaction to probenecid. Hillecke N, JAMA 1965 193 116
75. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, Misore A, Muga R, Oloo AJ, Steketee RW, Am J Trop Med Hyg 1998 59 813 822 9840604 (Pubitemid 28524544)
76. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M, J Infect Dis 2006 194 286 293 10.1086/505080 16826475 (Pubitemid 44116969)
77. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in hiv-seropositive pregnant Zambian Women. Hamer DH, Mwanakasale V, MacLeod WB, Chalwe V, Mukwamataba D, Champo D, Mwananyanda L, Chilengi R, Mubikayi L, Mulele CK, Mulenga M, Thea DM, Gill CJ, J Infect Dis 2007 196 11 1585 1594 10.1086/522142 18008241 (Pubitemid 351411955)
78. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (fansidar(r)) for malaria prophylaxis. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC, Am J Trop Med Hyg 1986 35 451 458 2939735 (Pubitemid 16089959)
79. Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis. Hellgren U, Rombo L, Berg B, Carlson J, Wiholm BE, BMJ 1987 295 365 366 3115450 (Pubitemid 17125762)
80. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. Phillips-Howard P, West LJ, J R Soc Med 1990 83 82 85 2138674 (Pubitemid 20159350)
81. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Gimnig JE, MacArthur JR, M'Bang'Ombe M, Kramer MH, Chizani N, Stern RS, Mkandala C, Newman RD, Steketee RW, Campbell CH, Am J Trop Med Hyg 2006 74 738 743 16687672 (Pubitemid 46774388)
82. Effect of Repeated treatment of pregnant women with sulfadoxine- pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P, Am J Trop Med Hyg 2010 83 1212 1220 10.4269/ajtmh.2010.10-0264 21118924
83. The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah. Khoo K, Ann Trop Med Parasitol 1981 75 591 595 7325735 (Pubitemid 12193933)
84. Treatment of gonorrhea in pregnancy. Cavenee MR, Farris JR, Spalding TR, Barnes DL, Castaneda YS, Wendel GD Jr, Obstet Gynecol 1993 81 33 38 8416458 (Pubitemid 23041699)
85. Treatment of urinary infections in pregnancy using single versus 10-day dosing. Adelson M, Graves WL, Osborne NG, J Natl Med Assoc 1992 84 73 75 1602504
86. The Renal clearance of endogenous estrogens in late pregnancy. Brown C, Saffan BD, Howard CM, Preedy JR, J Clin Invest 1964 43 295 303 10.1172/JCI104914 14164476
87. Gout and pregnancy. Lee FI, Loeffler FE, J Obstet Gynaecol Br Emp 1962 69 2 299 304 10.1111/j.1471-0528.1962.tb00046.x 14463488
88. Gout and Pregnancy. Weingold AB, Obstet Gynecol 1960 16 3 309 313 13843594
89. Hyperuricaemia and preeclampsia: is there a pathogenic link? Schackis RC, Med Hypotheses 2004 63 239 244 10.1016/j.mehy.2004.02.018 15236782 (Pubitemid 38968722)
90. Plasma uric acid levels, uric acid excretion, and response to probenecid in toxemia of pregnancy. Czaczkes W, Ullmann TD, Sadowsky E, J Lab Clin Med 1958 51 224 229 13514228
91. Folic acid antagonists during pregnancy and the risk of birth defects. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA, NEJM 2000 343 1608 1614 10.1056/NEJM200011303432204 11096168 (Pubitemid 32162984)
92. Organic anion transporter (Slc22a) family members as mediators of toxicity. Sweet D, Toxicol Appl Pharmacol 2005 204 198 215 10.1016/j.taap.2004. 10.016 15845414 (Pubitemid 40545228)
93. Organic anion transporter family: current knowledge. Anzai N, Kanai Y, Endou H, J Pharmacol Sci 2006 100 411 426 10.1254/jphs.CRJ06006X 16799257 (Pubitemid 44609532)
94. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus- infected patients. Cundy KC, Petty BG, Flaherty J, Fisher PE, Polis MA, Wachsman M, Lietman PS, Lalezari JP, Hitchcock MJ, Jaffe HS, Antimicrob Agents Chemother 1995 39 1247 1252 7574510
95. High-performance liquid chromatographic method for the determination of pyrimethamine and its 3-N-oxide metabolite in biological fluids. Coleman M, Edwards G, Mihaly GW, Howells RE, Breckenridge AM, J Chromatogr 1984 308 363 369 6746829 (Pubitemid 14119733)
96. High-performance liquid chromatographic assay for the determination of sulfadoxine and N-acetyl sulfadoxine in plasma from patients infected with sensitive and resistant Plasmodium falciparu malaria. Dua V, Gupta NC, Sethi P, Edwards G, Dash AP, J Chromatogr B Analyt Technol Biomed Life Sci 2007 860 160 165 10.1016/j.jchromb.2007.10.016 17997367 (Pubitemid 350181628)
97. World Health Organization, World Malaria Report 2009 Geneva: World Health Organization 2009
98. World Health Organization. Malaria in Pregnancy Working Group, Minutes of the 8th Strategic Planning Meeting Geneva: World Health Organization 2007